COLLEGIUM PHARMACEUTICAL INC

NASDAQ: COLL (Collegium Pharmaceutical, Inc.)

Kemas kini terakhir: 06 Jan, 12:08AM

45.68

0.15 (0.33%)

Penutupan Terdahulu 45.53
Buka 45.17
Jumlah Dagangan 641,719
Purata Dagangan (3B) 486,488
Modal Pasaran 1,443,989,376
Harga / Pendapatan (P/E TTM) 28.02
Harga / Pendapatan (P/E Ke hadapan) 6.33
Harga / Jualan (P/S) 2.46
Harga / Buku (P/B) 5.41
Julat 52 Minggu
23.23 (-49%) — 50.79 (11%)
Margin Keuntungan 6.61%
Margin Operasi (TTM) 13.71%
EPS Cair (TTM) 1.22
Pertumbuhan Hasil Suku Tahunan (YOY) 22.70%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -91.30%
Jumlah Hutang/Ekuiti (D/E MRQ) 411.94%
Nisbah Semasa (MRQ) 1.08
Aliran Tunai Operasi (OCF TTM) 198.44 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 341.32 M
Pulangan Atas Aset (ROA TTM) 7.95%
Pulangan Atas Ekuiti (ROE TTM) 19.23%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Bercampur Menaik
Drug Manufacturers - Specialty & Generic (Global) Menaik Menaik
Stok Collegium Pharmaceutical, Inc. Menaik Menaik

AISkor Stockmoo

1.0
Konsensus Penganalisis 4.0
Aktiviti Orang Dalam NA
Volatiliti Harga -0.5
Purata Bergerak Teknikal 1.0
Osilator Teknikal -0.5
Purata 1.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
COLL 1 B - 28.02 5.41
RGC 15 B - - 3.58
SUPN 3 B - - 2.72
ANIP 2 B - 53.14 3.77
DVAX 1 B - - 3.33
AMPH 1 B - 11.71 1.54

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 1.69%
% Dimiliki oleh Institusi 117.12%
Julat 52 Minggu
23.23 (-49%) — 50.79 (11%)
Julat Harga Sasaran
48.00 (5%) — 60.00 (31%)
Tinggi 60.00 (HC Wainwright & Co., 31.35%) Beli
Median 56.00 (22.59%)
Rendah 48.00 (Truist Securities, 5.08%) Beli
Purata 55.00 (20.40%)
Jumlah 4 Beli
Harga Purata @ Panggilan 45.54
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Barclays 09 Jan 2026 56.00 (22.59%) Beli 45.54
09 Dec 2025 58.00 (26.97%) Beli 47.03
HC Wainwright & Co. 09 Jan 2026 60.00 (31.35%) Beli 45.54
07 Nov 2025 46.00 (0.70%) Beli 42.30
Needham 08 Jan 2026 56.00 (22.59%) Beli 48.78
28 Oct 2025 46.00 (0.70%) Beli 35.41
Truist Securities 07 Nov 2025 48.00 (5.08%) Beli 42.30

Tiada data dalam julat masa ini.

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda